Benazepril Hydrochloride

• Antihypertensive Agents
• Angiotensin-converting Enzyme Inhibitors
• ATC:C09AA07

• Benazepril HCl
• Benazepril Hydrochloride
• Benazeprilum [Latin]
• Briem
• Cibacen
• Cibacene
• Lotensin

Lotensin HCT (Benazepril Hydrochloride + Hydrochlorothiazide)

Lotrel (Benazepril Hydrochloride + Amlodipine Besylate)

C₂₄H₂₈N₂O₅

http://www.rxlist.com/cgi/generic/benaz.htm

Benazepril_Hydrochloride FDA

Benazepril_Hydrochloride MSDS

USpat.4, 410.520 (1983)

424.49 g/mol

148-149 ^oC

2,229 mg / L

Solid

3.217

Comprimido (5 mg, 10 mg, 20 mg, 40 mg)

Para el tratamiento de la hipertensión. Se puede utilizar solo o en combinación con diuréticos tiazídicos.

Benazepril, un inhibidor de la enzima convertidora de angiotensina (ECA), es un profármaco que, cuando se hidroliza por estarases a su benazeprilato activo, se utiliza para tratar la hipertensión y la insuficiencia cardiaca, para reducir la proteinuria y la enfermedad renal en pacientes con nefropatías, y para evitar accidente cerebrovascular, infarto de miocardio y muerte cardíaca en pacientes de alto riesgo. Benazepril y benazeprilato inhibir la enzima convertidora de angiotensina (ACE) en seres humanos y animales. La ECA es una peptidil dipeptidasa que cataliza la conversión de angiotensina I en la sustancia vasoconstrictora de la angiotensina II. La angiotensina II también estimula la aldosterona la secreción de la corteza suprarrenal.

Pico en el plasma dentro de 0.5-1.0 horas. El grado de absorción es al menos el 37%, determinado mediante recuperación urinaria y no es significativamente influenciado por la presencia de alimentos en el tracto gastrointestinal.

Los síntomas de sobredosis incluyen inflamación de la cara, boca, manos o pies, dificultad para tragar o respirar (de repente), ronquera, fiebre y escalofríos.

Pregnancy

Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

Angioedema

Angioedema, including laryngeal edema, can occur at any time with treatment with ACE inhibitors. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

Symptomatic Hypotension

Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported to the prescribing physician. Patients should be told that if syncope occurs, Lotensin should be discontinued until the prescribing physician has been consulted.

All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

Hyperkalemia

Patients should be told not to use potassium supplements or salt substitutes containing potassium without consulting the prescribing physician.

Neutropenia

Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.

Humanos y otros mamíferos